# 2025年12月24日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 体外膜氧合支持儿童的血小板输注阈值：体外膜氧合儿童止血输注（ECSTATIC）可行性临床试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41432485)
**期刊：** Critical care medicine
**PMID：** 41432485
**DOI：** 10.1097/CCM.0000000000006995

### 第一部分 原文与翻译

**英文原标题：** Platelet Transfusion Thresholds for Children Supported by Extracorporeal Membrane Oxygenation: The Extracorporeal Membrane Oxygenation Hemostatic Transfusions in Children (ECSTATIC) Feasibility Clinical Trial.

> **英文摘要：**
> OBJECTIVES: To evaluate the feasibility of randomizing children on extracorporeal membrane oxygenation (ECMO) to one of two prophylactic platelet transfusion thresholds.
> 
> DESIGN: Randomized controlled trial.
> 
> SETTING: Ten ECMO centers (nine in United States, one in Israel).
> 
> PATIENTS: Critically ill children (0 to younger than 18 yr), supported on ECMO, with no or minimal bleeding within 24 hours of cannulation.
> 
> INTERVENTIONS: Children were randomized to a higher platelet threshold (transfused when platelet count < 90 × 109/L) or a lower platelet threshold (transfused when platelet count < 50 × 109/L). Primary feasibility outcome was pre-transfusion platelet count to test for a difference between strategies. Primary safety outcome was progression to severe bleeding, severe clotting, and/or all-cause mortality.
> 
> MEASUREMENTS AND MAIN RESULTS: Of 159 patients screened for eligibility, 77% (123/159) met eligibility criteria. Sixty-five percent (80/123) of caregivers were approached for consent. Consent was obtained in 63% (50/80). Enrolled children had a median age of 0.2 years (interquartile range 0.0; 1.7) and 88% (44/50) were supported by veno-arterial (V-A) ECMO. The model-adjusted mean difference in pre-transfusion platelet count between the groups was 32 × 109/L (p < 0.001). Compliance with assigned transfusion threshold was 99.2%. Eleven (22%) children experienced the primary safety outcome. Progression to severe bleeding occurred in 14% (7/50) of patients, whereas progression to severe clotting was observed in 4% (2/50).
> 
> CONCLUSIONS: Non-bleeding children on ECMO can be screened, enrolled and randomized to different platelet transfusion strategies within 24 hours of cannulation. Compliance with the protocol was excellent with significant separation in pre-transfusion platelet counts between the arms. Severe bleeding and severe clotting occurred at similar rates in both thresholds. A larger, definitive trial is feasible and needed.

> **中文摘要：**
> 研究目的：评估在体外膜氧合（ECMO）治疗期间，将儿童随机分配至两种不同预防性血小板输注阈值方案的可行性。
> 
> 研究设计：随机对照试验。
> 
> 研究场所：10个ECMO中心（美国9个，以色列1个）。
> 
> 研究对象：危重症儿童（年龄0至<18岁），接受ECMO治疗，导管插入后24小时内无出血或仅有轻微出血。
> 
> 干预措施：儿童被随机分配至较高血小板阈值组（当血小板计数<90×10⁹/L时输注）或较低血小板阈值组（当血小板计数<50×10⁹/L时输注）。主要可行性结局为输注前血小板计数，以检测两种策略间的差异。主要安全性结局包括严重出血、严重血栓形成和/或全因死亡的进展。
> 
> 测量与主要结果：在筛查的159名患儿中，77%（123/159）符合入组标准。65%（80/123）的照护者被邀请签署知情同意书，最终获得63%（50/80）的同意。入组儿童的年龄中位数为0.2岁（四分位距0.0; 1.7），其中88%（44/50）接受静脉-动脉（V-A）ECMO支持。两组间输注前血小板计数的模型调整均值差为32×10⁹/L（p < 0.001）。对指定输注阈值的依从性达99.2%。共有11名（22%）儿童出现主要安全性事件。严重出血进展发生于14%（7/50），严重凝血事件观察到于4%（2/50）。
> 
> 结论：未出血的ECMO患儿可在插管后24小时内被筛选、入组并随机分配至不同的血小板输注策略。研究方案的依从性极佳，且两组间输注前血小板计数存在显著差异。严重出血与严重血栓形成在两种阈值下发生率相似。进行更大规模、确证性的试验是可行且必要的。

### 第二部分 AI 大师评价

该研究首次系统性评估了ECMO治疗儿童中两种预防性血小板输注阈值的随机化可行性，体现了研究团队在极危重病儿群体中实施随机试验的能力。结果显示，入组与依从性良好，输注前血小板水平在两组之间得到显著区分，而严重出血与凝血事件发生率相似。此研究为未来制定更具证据基础的血小板输注标准奠定了基础，但样本量有限且仅为可行性研究，仍需大规模试验进一步验证其安全性与临床效果。

---

## 2. 接受连续肾脏替代治疗的危重成年患者中头孢他啶-阿维巴坦的药代动力学/药效学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41432444)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41432444
**DOI：** 10.1128/aac.01438-25

### 第一部分 原文与翻译

**英文原标题：** Pharmacokinetics/pharmacodynamics of ceftazidime-avibactam in critically ill adult patients receiving continuous renal replacement therapy.

> **英文摘要：**
> Ceftazidime-avibactam (CAZ-AVI), a novel antibiotic, is effective in treating infections caused by carbapenem-resistant Gram-negative bacteria. However, in patients receiving continuous renal replacement therapy (CRRT), both the pharmacokinetics (PK) and pharmacodynamics (PD) of the drugs can be significantly altered. Currently, there remains a lack of clear guidelines regarding optimal dosing regimens for CAZ-AVI during CRRT. Prospectively, this study evaluated the PK/PD of CAZ-AVI in 21 critically ill patients receiving CRRT. We collected blood samples at 5-7 sampling points within one administration cycle and then determined the total plasma drug concentrations. Phoenix was used to calculate the PK parameters. The clearance at steady state (CL) of patients receiving CRRT was significantly reduced, and drug exposure was also significantly increased compared to healthy subjects. Notably, four patients demonstrated the free minimum plasma concentrations (fC) of CAZ exceeding eight times the MIC, and 90.48% (19 cases) of the patients exhibited CAZ plasma concentrations exceeding the neurotoxicity threshold of 104 mg/L. PK/PD analysis indicated that the standard dosing regimen of 2.5 g every 8 hours of CAZ-AVI may pose a risk of excessive drug exposure. In addition, CRRT was the primary elimination pathway for CAZ-AVI in critically ill patients with acute kidney injury receiving CRRT. Significant differences in extracorporeal clearance were observed between continuous veno-venous hemodialysis (CVVHD) and continuous veno-venous hemofiltration (CVVH) for both CAZ and AVI; CVVH demonstrated higher clearance for CAZ and AVI compared to CVVHD. To prevent potential toxic reactions, it is urgent to establish a safer and more rational dosing regimen for patients receiving CRRT.

> **中文摘要：**
> 头孢他啶-阿维巴坦（CAZ-AVI）是一种新型抗生素，对由碳青霉烯耐药阴性菌引起的感染具有疗效。然而，在接受连续肾脏替代治疗（CRRT）的患者中，该药物的药代动力学（PK）和药效学（PD）可能发生显著改变。目前，对于CAZ-AVI在CRRT期间的最佳给药方案尚缺乏明确指南。本研究为前瞻性研究，在21例接受CRRT的危重患者中评估了CAZ-AVI的PK/PD特征。研究在一个给药周期内于5-7个采样点采集血样，并测定血浆总药物浓度。采用Phoenix软件计算PK参数。与健康受试者相比，接受CRRT的患者稳态清除率（CL）显著降低，而药物暴露显著增加。值得注意的是，4例患者的CAZ游离最低血浆浓度（fC）超过最低抑菌浓度（MIC）的8倍，且90.48%（19例）患者的CAZ血浆浓度超过神经毒性阈值104 mg/L。PK/PD分析显示，标准的CAZ-AVI 2.5 g每8小时给药方案可能导致药物暴露过高风险。此外，在伴急性肾损伤并接受CRRT的危重患者中，CRRT是CAZ-AVI的主要清除途径。在连续静脉-静脉血液透析（CVVHD）与连续静脉-静脉血液滤过（CVVH）之间，CAZ和AVI的体外清除率存在显著差异；CVVH对两种药物的清除率均高于CVVHD。为防止潜在毒性反应，亟需建立更安全和更合理的CRRT患者给药方案。

### 第二部分 AI 大师评价

该研究通过前瞻性收集危重CRRT患者的药代及药效数据，揭示了头孢他啶-阿维巴坦在此类患者中清除率显著下降、暴露升高的特点。结果指出，常规给药方案可能造成过量暴露及潜在神经毒性风险，同时揭示了CVVH与CVVHD在药物清除效率上的差异。研究为优化抗感染治疗策略、制定个体化CRRT给药方案提供了重要依据，但样本量有限，仍需进一步验证其临床推荐剂量的安全性与有效性。

---

## 3. 伊曲康唑和泊沙康唑最低抑菌浓度的梯度浓度试纸法与EUCAST方法比较研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41432408)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41432408
**DOI：** 10.1128/aac.01293-25

### 第一部分 原文与翻译

**英文原标题：** Comparison of gradient concentration strip and EUCAST methods for itraconazole and posaconazole MICs in .

> **英文摘要：**
> The increasing spread of antifungal-resistant dermatophytosis caused by  has become a major public health and therapeutic concern. Consequently, antifungal susceptibility testing in routine clinical laboratories is essential for effective patient management. Itraconazole is currently the recommended treatment for these infections. However, few molecular or phenotypic tools are available to assess susceptibility to azoles. In this context, we evaluated the itraconazole and posaconazole MICs obtained using gradient concentration strips (GCS), in comparison with the EUCAST reference method. A total of 73 clinical isolates belonging to the  complex, including 64  isolates, were analyzed. MIC readings for both methods were performed on days 5 and 7 at partial (80%) and complete (100%) inhibition. We found that the optimal reading frame is on day 5 at 100% growth inhibition. Essential agreement within ±1 dilution (and ±2 dilutions) for the GCS method versus the EUCAST method was 65.8% (89%) for itraconazole and 57.5% (83.6%) for posaconazole. The GCS test appears to be a valuable method for susceptibility screening of  clinical isolates, providing a practical option for routine laboratories despite essential agreement values below the ideal 90% threshold for method validation.

> **中文摘要：**
> 由耐药性皮肤癣菌引起的抗真菌耐药性皮肤癣感染传播日益增加，已成为重大的公共卫生与治疗问题。因此，在常规临床实验室中进行真菌药物敏感性试验对于有效的患者管理至关重要。伊曲康唑目前是治疗此类感染的推荐药物。然而，目前可用于评估唑类药物敏感性的分子或表型工具仍然有限。在此背景下，我们比较了使用梯度浓度试纸（GCS）法与EUCAST标准方法获得的伊曲康唑和泊沙康唑最低抑菌浓度（MIC）。共分析了73株属于该复合体的临床分离株，其中包括64株特定分离株。两种方法的MIC读数分别于第5天和第7天读取，抑制水平为部分（80%）和完全（100%）。结果显示，最佳读数时间为第5天、100%生长抑制时。与EUCAST方法相比，GCS方法在±1倍稀释（和±2倍稀释）范围内的基本一致性为：伊曲康唑分别为65.8%（89%），泊沙康唑分别为57.5%（83.6%）。尽管基本一致性值低于方法验证理想的90%阈值，GCS试验仍被认为是临床分离株耐药性筛查的有价值方法，为常规实验室提供了一种实用的选择。

### 第二部分 AI 大师评价

本研究旨在比较梯度浓度试纸法与EUCAST参考方法在测定伊曲康唑和泊沙康唑对皮肤癣菌最低抑菌浓度时的一致性与可行性。研究通过分析73株临床分离株的结果，确定了最佳读数条件为第5天、100%抑制水平。结果显示，两种方法间的一致性未达到理想验证阈值，但GCS法仍具实用价值。该研究揭示了现有抗真菌敏感性检测在皮肤癣菌领域的局限性，并为实验室提供了更具可操作性的替代方案。

---

## 4. VExUS 与右心室–肺动脉耦合失调的关系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41430734)
**期刊：** Critical care (London, England)
**PMID：** 41430734
**DOI：** 10.1186/s13054-025-05806-9

### 第一部分 原文与翻译

**英文原标题：** VExUS and right ventricular to pulmonary artery uncoupling.

> **英文摘要：**
> The VExUS score is meant to alert the clinician to an uncoupling at the right ventricular (RV)-pulmonary artery (PA) interface. Bedside ultrasonography and determination of the etiology of an abnormal VExUS score is the first step.

> **中文摘要：**
> VExUS 评分旨在提醒临床医生注意右心室（RV）与肺动脉（PA）之间的耦合失调。进行床旁超声检查并确定异常 VExUS 评分的病因是首要步骤。

### 第二部分 AI 大师评价

该研究聚焦于VExUS评分在识别右心室与肺动脉耦合失调中的临床应用价值，提示其不仅是血流动力学评估工具，更是右心功能障碍的早期预警指标。作者强调了床旁超声在快速评估及病因溯源中的关键作用。此研究突出了以影像学评分预测右心病理生理变化的理念，但受限于摘要篇幅，研究细节及验证数据尚需进一步探索。

---

## 5. 脓毒症患者体液免疫蛋白与死亡率的系统综述与荟萃分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41430733)
**期刊：** Critical care (London, England)
**PMID：** 41430733
**DOI：** 10.1186/s13054-025-05758-0

### 第一部分 原文与翻译

**英文原标题：** Systematic review and meta-analysis of humoral immunity proteins and mortality in sepsis.

> **英文摘要：**
> PURPOSE: Humoral immunity proteins-immunoglobulins, complement proteins, and antimicrobial peptides-have key antimicrobial and immunomodulatory functions in sepsis. We hypothesised that their circulating levels are lower in non-survivors, potentially resulting in impaired bacterial clearance and persistent or recurrent infections.
> 
> METHODS: We performed a systematic review and meta-analysis evaluating differences in humoral immunity proteins between survivors and non-survivors in adult patients with sepsis. PubMed and Embase were searched without date restrictions. Random-effects meta-analyses were used to estimate pooled standardised mean differences (SMD) with 95% confidence intervals (CI). Sensitivity analyses included data from the MIMIC-IV ICU database, and further supplemented by three proteomic studies.
> 
> RESULTS: Thirty-six studies including 6,330 patients were analysed. Thirteen reported on immunoglobulins, 17 on complement proteins, and 7 on the antimicrobial peptide heparin-binding protein (HBP). Survivors had significantly higher levels of complement proteins C3 (SMD 0.53 [0.07-0.99]) and C4 (SMD 0.51 [0.09-0.94]) compared to non-survivors. Conversely, C4a (SMD - 1.17 [-1.77 to - 0.56]) and IgA (SMD - 0.21 [-0.39 to - 0.03]) were significantly lower in survivors. No differences were found for IgG (SMD 0.00 [-0.18 to 0.18]), IgM (SMD - 0.02 [-0.13 to 0.08]), C5, C5a, or HBP. Sensitivity analyses using MIMIC-IV (n = 2,452) and proteomic datasets supported these findings. Proteomic data revealed early depletion of classical complement components (C3, C4B) and regulatory proteins in non-survivors.
> 
> CONCLUSION: Sepsis non-survivors exhibit lower C3 and C4 levels and higher C4a, consistent with complement activation and/or depletion. Complement proteins may serve as potential biomarkers and therapeutic targets in sepsis.

> **中文摘要：**
> 目的：体液免疫蛋白——免疫球蛋白、补体蛋白及抗菌肽——在脓毒症中具有关键的抗菌及免疫调节功能。我们假设，在未存活的脓毒症患者中，这些蛋白的循环水平较低，可能导致细菌清除能力受损以及持续或反复感染。
> 
> 方法：本研究进行了一项系统综述与荟萃分析，评估成人脓毒症患者中生存者与未生存者之间体液免疫蛋白水平的差异。检索了 PubMed 与 Embase 数据库，对时间不设限。采用随机效应荟萃分析模型估计合并标准化均数差（SMD）及其 95% 置信区间（CI）。敏感性分析包括来自 MIMIC-IV 重症监护数据库的数据，并补充分析了三项蛋白质组学研究。
> 
> 结果：共纳入36项研究，涉及6,330名患者。其中13项研究报道免疫球蛋白，17项研究报道补体蛋白，7项研究报道抗菌肽肝素结合蛋白（HBP）。与未生存者相比，生存者的补体蛋白C3（SMD 0.53 [0.07–0.99]）与C4（SMD 0.51 [0.09–0.94]）水平均显著较高；相反，生存者的C4a（SMD -1.17 [-1.77 至 -0.56]）及IgA（SMD -0.21 [-0.39 至 -0.03]）水平均显著较低。IgG（SMD 0.00 [-0.18 至 0.18]）、IgM（SMD -0.02 [-0.13 至 0.08]）、C5、C5a及HBP均未发现差异。利用MIMIC-IV（n=2,452）及蛋白质组学数据进行的敏感性分析支持上述结果。蛋白质组学结果显示，未生存者早期出现经典补体成分（C3、C4B）及调节蛋白的耗竭。
> 
> 结论：脓毒症未生存者表现出较低的C3和C4水平以及较高的C4a水平，提示存在补体激活和/或耗竭状态。补体蛋白可能成为脓毒症潜在的生物标志物及治疗靶点。

### 第二部分 AI 大师评价

该研究通过系统综述与荟萃分析定量整合了脓毒症患者体液免疫蛋白的研究证据，揭示了补体C3、C4水平降低与死亡相关联。研究方法严谨，结合了多源数据（包括MIMIC-IV数据库和蛋白质组学研究），增强了结果的可靠性。发现提示补体激活或耗竭在病情恶化中起重要作用，为脓毒症早期识别和靶向治疗提供潜在方向。但部分蛋白如IgG、IgM无显著差异，提示仍需进一步机制研究与临床验证。

---

## 6. 中性粒细胞介导的杂交跨物种纳米囊泡递送用于细菌感染治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41430080)
**期刊：** Nature communications
**PMID：** 41430080
**DOI：** 10.1038/s41467-025-67639-y

### 第一部分 原文与翻译

**英文原标题：** Neutrophil-mediated delivery of hybrid cross-species nanovesicles for treatment of bacterial infections.

> **英文摘要：**
> Hybrid vesicles are increasingly employed as nanocarrier systems for drug delivery owing to their versatile functionalities. This study presents a multifunctional vesicle delivery platform, designated PMB@LNV-SyBV, which integrates anti-inflammatory lemon-derived exosomes and attenuated bacterial vesicles to deliver polymyxin B (PMB). The incorporation of exogenous cholesterol enhances the drug-loading capacity of these vesicles. Antimicrobial assays confirm that PMB@LNV-SyBV effectively targets carbapenem-resistant Gram-negative bacteria. By inheriting pathogen-associated molecular patterns from native bacteria, PMB@LNV-SyBV is efficiently recognized and internalized by neutrophils, enabling it to reach infection sites alongside neutrophil recruitment. Subsequently, the vesicles are released from neutrophils in response to inflammatory stimuli. In infection models involving Klebsiella pneumoniae-induced mouse pneumonia and K. pneumoniae/Escherichia coli-induced mouse bloodstream infections, PMB@LNV-SyBV significantly reduces bacterial load, modulates pro-inflammatory cytokine release, and increases sepsis survival rates. With its high yield and favorable biocompatibility, the multifunctional PMB@LNV-SyBV represents a promising therapeutic platform for the clinical management of carbapenem-resistant bacterial infections.

> **中文摘要：**
> 由于其多样化的功能，杂交囊泡正越来越多地被用于药物递送的纳米载体系统。本研究提出了一种多功能囊泡递送平台，命名为 PMB@LNV-SyBV，该平台将具有抗炎特性的柠檬来源外泌体与减毒细菌囊泡相结合，用于递送多粘菌素 B（PMB）。外源胆固醇的引入提高了这些囊泡的载药能力。抗菌实验表明，PMB@LNV-SyBV 能有效靶向碳青霉烯耐药的革兰氏阴性菌。由于继承了来源菌的病原相关分子模式，PMB@LNV-SyBV 可被中性粒细胞高效识别并内吞，从而在中性粒细胞募集的同时抵达感染部位。随后，囊泡会在炎症刺激下从中性粒细胞中释放出来。在由肺炎克雷伯菌诱导的小鼠肺炎模型和由肺炎克雷伯菌/大肠杆菌诱导的小鼠血流感染模型中，PMB@LNV-SyBV 显著降低了细菌负荷，调节了促炎细胞因子释放，并提高了脓毒症的存活率。凭借较高的产率和良好的生物相容性，该多功能 PMB@LNV-SyBV 平台为临床管理碳青霉烯耐药性细菌感染提供了有前景的治疗策略。

### 第二部分 AI 大师评价

本研究设计了一种结合植物来源外泌体与减毒细菌囊泡的新型混合纳米载体，创新性地利用中性粒细胞递送机制，实现针对耐药革兰氏阴性菌的靶向治疗。通过体内外实验验证，该系统可有效递送多粘菌素 B，减轻炎症反应并改善感染模型的生存结局。研究的亮点在于跨物种囊泡整合与免疫细胞介导运输的协同策略。然而，其在复杂临床环境中的免疫安全性和大规模制备稳定性仍需进一步验证。

---

## 7. 基于 Charité 血浆蛋白质组学开放标准（OSPP）的跨平台临床蛋白质组学研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41430040)
**期刊：** Nature communications
**PMID：** 41430040
**DOI：** 10.1038/s41467-025-67264-9

### 第一部分 原文与翻译

**英文原标题：** Cross-platform clinical proteomics using the Charité open standard for plasma proteomics (OSPP).

> **英文摘要：**
> The role of plasma and serum proteomics in characterizing human disease, identifying biomarkers, and advancing diagnostic technologies is rapidly increasing. However, there is an ongoing need to improve proteomic workflows in terms of accuracy, reproducibility, and cost-effectiveness, and to achieve cross-platform transferability. Based on large serum and plasma proteome studies, we generate the Charité Open Peptide Standard for Plasma Proteomics (OSPP), an open, versatile peptide internal standard for targeted and untargeted mass spectrometry-based proteomic studies. The OSPP includes 211 concentration-matched stable-isotope-labeled peptides selected for consistent quantification across a large number of plasma and serum proteome studies, and synthetic accessibility. We show they are consistently quantified across serum and EDTA, citrate, and heparin plasma using multiple LC-MS platforms. Despite being selected for technical parameters, the OSPP peptides represent proteins that function in a wide range of biological processes, are used in routine clinical tests, or are targets of FDA-approved drugs, making OSPP able to serve as an expandable clinical marker panel. We demonstrate the utility of OSPP in a COVID-19 inpatient cohort study for improving analytical performances, for cross-platform alignment of proteomic data, disease stratification, and biomarker discovery.

> **中文摘要：**
> 血浆和血清蛋白质组学在表征人类疾病、识别生物标志物以及推动诊断技术发展方面的作用正在迅速提升。然而，蛋白质组学工作流程在准确性、可重复性和成本效益方面仍需改进，同时还需要实现跨平台可转移性。基于大规模血清和血浆蛋白质组研究，我们建立了 Charité 血浆蛋白质组学开放肽标准（OSPP），该标准是一种开放且多用途的肽类内标，可用于基于靶向和非靶向质谱的蛋白质组学研究。OSPP 包含 211 种浓度匹配的稳定同位素标记肽，这些肽基于大量血浆和血清蛋白质组学研究被筛选，以确保定量的一致性及合成可行性。我们证明，这些肽在多种 LC-MS 平台上可在血清及 EDTA、柠檬酸盐和肝素血浆中实现一致的定量。尽管这些肽的选择基于技术指标，但它们对应的蛋白质涉及广泛的生物学过程，被用于常规临床检测，或作为 FDA 批准药物的靶点，因此 OSPP 有潜力作为可扩展的临床标志物面板。我们在一项 COVID-19 住院患者队列研究中展示了 OSPP 的应用价值，可改善分析性能，促进蛋白质组数据的跨平台比对、疾病分层及生物标志物发现。

### 第二部分 AI 大师评价

该研究旨在解决临床蛋白质组学中跨平台可比性和定量一致性不足的问题，提出并验证了 Charité 血浆蛋白质组学开放肽标准（OSPP）。作者通过系统筛选并验证 211 种稳定同位素标记肽，建立了一个可在多平台 LC-MS 系统中稳定使用的标准体系。研究在 COVID-19 患者队列中展示了该标准在数据对齐、疾病分层及标志物发现中的实际效用。此方法的创新性在于提供了开放、可扩展且临床相关的标准体系，但仍需在更多疾病模型与分析环境中进一步验证其泛化性能。

---

## 8. 原癌基因 c-Kit 在结节性硬化症肾囊肿形成中的关键作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41429944)
**期刊：** EMBO molecular medicine
**PMID：** 41429944
**DOI：** 10.1038/s44321-025-00360-x

### 第一部分 原文与翻译

**英文原标题：** The critical role of the proto-oncogene c-Kit in TSC renal cystogenesis.

> **英文摘要：**
> The epithelium of kidney cysts in mouse Tuberous Sclerosis complex (TSC) models and TSC patients is composed of proliferating A-intercalated cells. The ablation of the Foxi1 gene abolished renal cystogenesis in principal cell-specific Tsc1 knockout (Tsc1-KO) mice. RNAseq studies comparing kidneys of Tsc1-KO vs. wild-type (WT) and Tsc1/Foxi1-double-knockout identified c-Kit, a tyrosine kinase receptor (RTK), as a transcript whose expression significantly increased in Tsc1-KO mice. Overexpression of FOXI1 in kidney M-1 cells significantly increased c-Kit expression levels. Kidney cystogenesis was abolished in Tsc1-KO mice by inactivating the c-Kit gene via the generation of Tsc1/c-Kit-double-knockout mice. The treatment of Tsc1-KO mice with Imatinib, a specific inhibitor of c-KIT, significantly diminished kidney cystogenesis. Renal cystogenesis was associated with ERK1/2, AKT, and RSK1-mediated phospho-inactivation of TSC2. In contrast, activation of ERK1/2, AKT, and RSK1, as well as phosphorylation of TSC2, was notably reduced in the kidneys of Tsc1/c-Kit-dKO mice. We propose that c-KIT is a crucial mediator of TSC renal cystogenesis and that its inhibition may constitute a novel approach for the treatment of kidney cysts in TSC.

> **中文摘要：**
> 在小鼠结节性硬化症复合体（TSC）模型和 TSC 患者中，肾囊肿的上皮由增殖的 A 型插入细胞组成。敲除 Foxi1 基因可消除主细胞特异性 Tsc1 敲除（Tsc1-KO）小鼠的肾囊肿形成。RNA 测序对比了 Tsc1-KO 与野生型（WT）以及 Tsc1/Foxi1 双敲小鼠的肾组织，发现 c-Kit（一种酪氨酸激酶受体，RTK）在 Tsc1-KO 小鼠中显著上调。在肾脏 M-1 细胞中过表达 FOXI1 可显著增加 c-Kit 的表达水平。通过生成 Tsc1/c-Kit 双敲除小鼠使 c-Kit 基因失活，可消除 Tsc1-KO 小鼠的肾囊肿形成。用 c-KIT 特异性抑制剂伊马替尼治疗 Tsc1-KO 小鼠，可显著减轻肾囊肿形成。肾囊肿形成与 ERK1/2、AKT 和 RSK1 介导的 TSC2 磷酸化失活相关。相比之下，在 Tsc1/c-Kit 双敲除小鼠的肾脏中，ERK1/2、AKT 和 RSK1 的活化以及 TSC2 的磷酸化均明显减少。我们提出，c-KIT 是 TSC 肾囊肿形成的关键介导因子，其抑制可能构成治疗 TSC 相关肾囊肿的一种新策略。

### 第二部分 AI 大师评价

本研究揭示了 c-KIT 在结节性硬化症相关肾囊肿形成中的核心调控作用。作者通过遗传学双敲实验、RNAseq 分析及药物干预，系统地证实了 c-KIT 激活信号与 TSC2 失活及下游 ERK/AKT 通路活化的关联。结果显示，无论基因敲除或伊马替尼抑制均显著减少肾囊肿形成，提示 c-KIT 是潜在的治疗靶点。该研究在机制阐明和转化治疗方向上具有创新性，但仍需进一步验证其在人类肾组织及临床模型中的适用性。

---

## 9. 复杂的多年周期：持久性与随机性的作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41428876)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41428876
**DOI：** 10.1073/pnas.2509184122

### 第一部分 原文与翻译

**英文原标题：** Complex multiannual cycles of : Persistence and the role of stochasticity.

> **英文摘要：**
> The epidemiological dynamics of  is characterized by poorly understood complex multiannual cycles. The origins of these cycles have long been debated, and multiple explanations of varying complexity have been suggested. Using Bayesian methods, we fit a dynamical model to half a century of  surveillance data from Denmark (1958 to 1995, 2010 to 2025) and uncover a parsimonious explanation for the persistent cycles, based on the theory of quasicycles. The period of the multiannual cycle (approx. 5 y in Denmark) is explained by susceptible replenishment due, primarily, to loss of immunity. While an excellent fit to shorter time series (a few decades), the deterministic model eventually settles into an annual cycle, unable to reproduce the persistent cycles. We find that environmental stochasticity (e.g., varying contact rates) stabilizes the multiannual cycles and so does demographic noise, at least in smaller or incompletely mixing populations. The temporary disappearance of cycles during 1979 to 1985 is explained as a consequence of stochastic mode-hopping. The circulation of  was recently disrupted by COVID-19 nonpharmaceutical interventions (NPIs), providing a natural experiment on the effects of large perturbations. Consequently, the effects of NPIs are included in the model and medium-term predictions are explored. Our findings highlight the intrinsic sensitivity of  dynamics to perturbations and interventions, underscoring the limitations for long-term prediction. More generally, our findings provide further evidence for the role of stochasticity as a driver of complex cycles across endemic and recurring pathogens.

> **中文摘要：**
> 的流行病学动力学以复杂且尚未充分理解的多年周期为特征。这些周期的起源长期存在争议，已有多种不同复杂程度的解释被提出。我们采用贝叶斯方法，对丹麦长达半个世纪的监测数据（1958–1995 年，2010–2025 年）进行动力学建模拟合，并基于准周期理论揭示了一种简明的、可解释的持久周期形成机制。多年周期的周期长度（在丹麦约为 5 年）主要归因于易感个体的再补充，尤其是由于免疫力丧失所致。尽管确定性模型能够很好地拟合较短时间序列（数十年），但最终会收敛到年度周期，无法再现持续存在的多年周期。我们发现，环境随机性（例如接触率变化）可以稳定多年周期，人口随机噪声也具有类似效应，特别是在规模较小或混合不完全的人群中。1979 至 1985 年期间周期的暂时消失，可以解释为随机模式跳跃（stochastic mode-hopping）的结果。COVID-19 非药物干预措施（NPIs）近期扰乱了 的传播，为研究重大外部扰动效应提供了天然实验。因此，我们在模型中纳入了 NPIs 的效应，并探讨了其中期预测。我们的研究结果表明， 的动力学对扰动与干预高度敏感，凸显了长期预测的不确定性。更广泛地说，我们的研究进一步支持随机性作为地方性和复发性病原体复杂周期驱动力的作用。

### 第二部分 AI 大师评价

本研究旨在阐明某感染性病原体复杂多年周期的形成机制，利用丹麦半个世纪的监测数据结合贝叶斯建模，对其持续性和随机性影响进行系统分析。作者发现，确定性模型虽能再现短期动态，但需引入环境与人口随机性才能维持长期多年度周期。文章创新性地通过“准周期”理论解释了流行病动力学中的随机稳定机制，并以 COVID-19 干预措施作为自然实验验证假说。该研究为理解地方性病原体复杂波动提供了新视角，但模型对长期预测的敏感性提示需谨慎解读。

---

## 10. Nirsevimab 与 RSVpreF 疫苗在新生儿呼吸道合胞病毒相关住院预防中的比较

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41428474)
**期刊：** JAMA
**PMID：** 41428474
**DOI：** 10.1001/jama.2025.24082

### 第一部分 原文与翻译

**英文原标题：** Nirsevimab vs RSVpreF Vaccine for Respiratory Syncytial Virus-Related Hospitalization in Newborns.

> **英文摘要：**
> IMPORTANCE: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants. The comparative effectiveness of 2 recently introduced preventive strategies (infant immunization through placental antibody transfer after maternal vaccination with the RSV prefusion F protein [RSVpreF] vaccine and passive infant immunization with nirsevimab) remains unknown.
> 
> OBJECTIVE: To compare the associations of maternal vaccination with the RSVpreF vaccine vs passive infant immunization with nirsevimab for the prevention of RSV-related hospitalization.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study used data from the French National Health Data System. Maternal vaccination with the RSVpreF vaccine occurred during 32 to 36 weeks' gestation among infants born in mainland France between September 1 and December 31, 2024. Passive infant immunization with nirsevimab occurred prior to hospital discharge. Infants were matched 1:1 by maternity ward discharge date, sex, gestational age, and region. Follow-up ended at the time of RSV hospitalization or death or on February 28, 2025.
> 
> EXPOSURES: Maternal immunization with the RSVpreF vaccine and passive infant immunization with nirsevimab.
> 
> MAIN OUTCOMES AND MEASURES: The primary outcome was hospitalization for RSV-associated lower respiratory tract infection. The secondary outcomes included admission to the pediatric intensive care unit (PICU), admission to high-dependency unit, ventilator support, and oxygen therapy. The hazard ratios (HRs) were estimated using conditional Cox proportional hazards models with inverse probability of treatment weighting.
> 
> RESULTS: A total of 42 560 infants (mean age, 3.7 [SD, 1.4] days; 51.7% male) were included in the study (21 280 per group) with a median follow-up of 84 days (IQR, 70-99 days). Of the 481 hospitalizations for RSV-associated lower respiratory tract infection, 212 (44.1%) occurred in the nirsevimab group vs 269 (55.9%) in the RSVpreF vaccine group (between-group difference, -11.8% [95% CI, -18.1% to -5.5%]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of hospitalization for RSV-associated lower respiratory tract infection (adjusted HR, 0.74 [95% CI, 0.61 to 0.88]). Compared with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with a lower risk of severe outcomes, including PICU admission (adjusted HR, 0.58 [95% CI, 0.42 to 0.80]), requiring ventilator support (adjusted HR, 0.57 [95% CI, 0.40 to 0.81]), or requiring oxygen therapy (adjusted HR, 0.56 [95% CI, 0.38 to 0.81]). The results were consistent across subgroups and in the sensitivity analyses.
> 
> CONCLUSIONS AND RELEVANCE: Compared with maternal vaccination with the RSVpreF vaccine, passive infant immunization with nirsevimab was associated with lower risks of RSV-related hospitalization and severe outcomes. These findings reflect the first RSV season with use of these immunization strategies in mainland France; their use should be reevaluated in future studies.

> **中文摘要：**
> 重要性：呼吸道合胞病毒（RSV）是婴幼儿住院的主要原因之一。近期引入的两种预防策略 —— 产妇接种 RSV 前融合 F 蛋白（RSVpreF）疫苗后经胎盘抗体转移实现婴儿主动免疫，以及婴儿被动免疫用单克隆抗体 nirsevimab —— 其比较效果尚不明确。
> 
> 研究目的：比较产妇接种 RSVpreF 疫苗与婴儿被动免疫 nirsevimab 在预防 RSV 相关住院方面的关联。
> 
> 研究设计、地点与参与者：这项基于人群的队列研究使用法国国家健康数据系统的数据。产妇在妊娠 32 至 36 周期间接种 RSVpreF 疫苗，研究对象为 2024 年 9 月 1 日至 12 月 31 日间在法国本土出生的婴儿；婴儿在出院前接受 nirsevimab 被动免疫。研究按产科出院日期、性别、胎龄及地区进行 1:1 匹配。随访至发生 RSV 住院、死亡或截至 2025 年 2 月 28 日。
> 
> 暴露因素：母体 RSVpreF 疫苗主动免疫与婴儿 nirsevimab 被动免疫。
> 
> 主要结局与测量：主要结局为 RSV 相关下呼吸道感染住院。次要结局包括儿科重症监护（PICU）入院、高依赖病区（HDU）入院、呼吸机支持及氧疗。风险比（HR）通过逆概率加权的条件 Cox 比例风险模型估计。
> 
> 结果：研究共纳入 42 560 名婴儿（平均年龄 3.7 [标准差 1.4] 天；其中 51.7% 为男性），每组各 21 280 名，中位随访时间为 84 天（四分位距 70–99 天）。共有 481 例 RSV 相关下呼吸道感染住院，其中 nirsevimab 组 212 例（44.1%），RSVpreF 疫苗组 269 例（55.9%），两组差异为 -11.8%（95% 置信区间 -18.1% 至 -5.5%）。与 RSVpreF 疫苗相比，nirsevimab 被动免疫与较低的 RSV 相关住院风险相关（调整后 HR 0.74，95% CI 0.61–0.88）。nirsevimab 组在严重结局方面亦表现出较低风险，包括 PICU 入院（调整后 HR 0.58，95% CI 0.42–0.80）、呼吸机支持（调整后 HR 0.57，95% CI 0.40–0.81）及氧疗（调整后 HR 0.56，95% CI 0.38–0.81）。亚组分析及敏感性分析结果一致。
> 
> 结论与意义：与母体 RSVpreF 疫苗接种相比，婴儿被动免疫 nirsevimab 与更低的 RSV 相关住院及重症风险相关。本研究反映了法国本土首个应用这两种免疫策略的 RSV 季节，未来应持续评估其长期效果与适用性。

### 第二部分 AI 大师评价

该研究基于法国全国健康数据库，比较了母体接种 RSVpreF 疫苗与婴儿注射 nirsevimab 在预防新生儿 RSV 相关住院中的效果。结果显示，nirsevimab 被动免疫显著降低了住院及重症风险，提示其在首个应用季节表现出更优的保护力。研究样本量大、匹配严格，增进了真实世界证据的代表性。然而，随访时间较短、适用地区有限，仍需进一步多中心长期评估以验证结果的普适性。

---

## 11. TRAF1 通过增强 NOS2 的表达与活性抑制巨噬细胞对申克放线孢子菌的杀灭作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41428466)
**期刊：** The Journal of infectious diseases
**PMID：** 41428466
**DOI：** 10.1093/infdis/jiaf646

### 第一部分 原文与翻译

**英文原标题：** TRAF1 Inhibits Macrophage Killing of Sporothrix schenckii by Enhancing NOS2 Expression and Activity.

> **英文摘要：**
> BACKGROUND: Sporotrichosis is a chronic, deep fungal infection of skin caused by S.schenckii. Macrophages are predominant in S.schenckii infected skin and able to phagocytize and kill the fungus. Local hyperthermia is effective to treat sporotrichosis, however, its mechanism of action remains not fully understood.
> 
> METHODS: Using single-cell RNA sequencing of sporotrichosis lesions, coupled with in vitro and in vivo sporotrichosis models, we investigated the role of TRAF1 and NOS2. Mechanistic studies included co-immunoprecipitation, ubiquitination assays, and site-directed mutagenesis. Therapeutic mechanism of hyperthermia were evaluated in vivo and in vitro.
> 
> RESULTS: We demonstrated for the first time that TRAF1 could delay the healing of sporotrichosis by inhibiting phagocytosis and killing of macrophages to S.schenckii. This effect of TRAF1 is caused by binding NOS2 to regulate its expression and enzymatic activity, through inhibition of NOS2 ubiquitination and subsequent proteasome-induced degradation. Our team's previous research has demonstrated the efficacy of hyperthermia in treating sporotrichosis. Our experiments indicate that hyperthermia can downregulate the expression of TRAF1 and NOS2 in macrophages.
> 
> CONCLUSIONS: We identify TRAF1-mediated stabilization of NOS2 as a key immune evasion mechanism in S. schenckii infection. Local hyperthermia represents a targeted therapy against this pathway, offering a novel strategy for enhancing the therapeutic effect of hyperthermia.

> **中文摘要：**
> 背景：孢子丝菌病是一种由申克放线孢子菌（Sporothrix schenckii）引起的慢性深部皮肤真菌感染。巨噬细胞在 S. schenckii 感染的皮肤中占主导地位，能够吞噬并杀灭真菌。局部热疗对治疗孢子丝菌病有效，然而其作用机制尚未完全明了。
> 
> 方法：我们利用孢子丝菌病病灶的单细胞 RNA 测序，结合体内外孢子丝菌病模型，研究了 TRAF1 和 NOS2 的作用。机制研究包括共免疫沉淀、泛素化实验以及定点突变分析。同时在体内和体外评估了热疗的治疗机制。
> 
> 结果：我们首次证明，TRAF1 可通过抑制巨噬细胞对 S. schenckii 的吞噬与杀灭作用从而延迟孢子丝菌病的愈合。该作用由 TRAF1 与 NOS2 结合介导，调控其表达和酶活性，通过抑制 NOS2 的泛素化及其经蛋白酶体诱导的降解来实现。我们此前的研究已证实热疗治疗孢子丝菌病的有效性。本研究进一步显示，热疗可下调巨噬细胞中 TRAF1 和 NOS2 的表达。
> 
> 结论：我们确认 TRAF1 介导的 NOS2 稳定化是 S. schenckii 感染中一种关键的免疫逃逸机制。局部热疗可针对该通路发挥作用，代表了一种增强热疗治疗效果的新策略。

### 第二部分 AI 大师评价

该研究聚焦于 TRAF1 在孢子丝菌病巨噬细胞免疫反应中的调控作用，结合单细胞测序、体内外模型及分子机制实验，揭示 TRAF1 通过抑制 NOS2 泛素化和降解延缓病灶愈合。作者进一步发现热疗可下调 TRAF1/NOS2 表达，从而改善抗真菌效应。这为理解孢子丝菌病的免疫逃逸机制及优化热疗提供了新视角。研究创新性突出，但尚需探明热疗调控 TRAF1 的上游信号途径。

---

速递结束，祝您工作愉快！